We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Moderna, Inc. (MRNA - Free Report) is scheduled to report second-quarter 2020 results on Aug 5, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.41%.
The company’s earnings beat the Zacks Consensus Estimate in each of the last four quarters with the average surprise being 8.92%.
Moderna’s share price has surged 308.5% so far this year compared with the industry’s increase of 5%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Moderna has no marketed products in its portfolio. On the second-quarter earnings call, investor focus will likely remain on the progress of Moderna’s pipeline candidate, especially coronavirus vaccine candidate.
The company has been actively engaged in developing its coronavirus vaccine — mRNA-1273. It is one of the leading players in this field with phase III study initiated earlier this week. The company is conducting the study in collaboration with the National Institute of Allergy and Infectious Diseases. Interim data from a phase I study evaluating mRNA-1273 had shown rapid and strong immune responses against SARS-CoV-2 in all patients.
Moreover, Moderna has also been focusing on building manufacturing capacity for mRNA-1273 through collaborations. Last month, the company signed a manufacturing agreement with drug delivery specialist, Catalent, Inc. (CTLT - Free Report) and Spain-based Laboratorios Farmaceuticos Rovi for the same. It had earlier stated that it is on track to deliver 500 million doses of 100 μg dosage of mRNA-1273 per year, which can possibly increase up to 1 billion doses per year, beginning 2021.
Moreover, the company has received commitment for funding of approximately $955 million from the Biomedical Advanced Research and Development Authority to support development of the vaccine.
Investors will likely ask questions related to the progress of the phase II study on mRNA-1273 and try to gain an early insight into the phase III study on the second-quarter earnings call.
Apart from mRNA-1273, Moderna is developing several other mRNA-based products targeting different indications including cancer. The company also has collaborations under which its partners use its mRNA technology for development of therapies targeting different indications. The partners pay milestone payments to Moderna, which comprise its total revenues. These revenues can vary every quarter. In the past few quarters, revenues have declined year over year due to lower collaboration revenues across its strategic alliances, particularly with AstraZeneca (AZN - Free Report) and Merck. We do not expect second-quarter results to reflect any improvement.
In March, Moderna provided an update on the impact of coronavirus pandemic on its ongoing clinical studies evaluating its pipeline candidates. The company had paused enrollment in studies evaluating its rare disease candidates and respiratory vaccine candidate. We expect it to provide an update on the future path of these clinical studies on the call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Moderna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Moderna’s Earnings ESP is -0.93%. The Zacks Consensus Estimate is pegged at a loss of 36 cents.
Zacks Rank: Moderna currently has a Zacks Rank #2.
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
Image: Bigstock
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
Moderna, Inc. (MRNA - Free Report) is scheduled to report second-quarter 2020 results on Aug 5, before market open. In the last reported quarter, the company delivered an earnings surprise of 5.41%.
The company’s earnings beat the Zacks Consensus Estimate in each of the last four quarters with the average surprise being 8.92%.
Moderna’s share price has surged 308.5% so far this year compared with the industry’s increase of 5%.
Let’s see how things have shaped up for this announcement.
Factors to Note
Moderna has no marketed products in its portfolio. On the second-quarter earnings call, investor focus will likely remain on the progress of Moderna’s pipeline candidate, especially coronavirus vaccine candidate.
The company has been actively engaged in developing its coronavirus vaccine — mRNA-1273. It is one of the leading players in this field with phase III study initiated earlier this week. The company is conducting the study in collaboration with the National Institute of Allergy and Infectious Diseases. Interim data from a phase I study evaluating mRNA-1273 had shown rapid and strong immune responses against SARS-CoV-2 in all patients.
Moreover, Moderna has also been focusing on building manufacturing capacity for mRNA-1273 through collaborations. Last month, the company signed a manufacturing agreement with drug delivery specialist, Catalent, Inc. (CTLT - Free Report) and Spain-based Laboratorios Farmaceuticos Rovi for the same. It had earlier stated that it is on track to deliver 500 million doses of 100 μg dosage of mRNA-1273 per year, which can possibly increase up to 1 billion doses per year, beginning 2021.
Moreover, the company has received commitment for funding of approximately $955 million from the Biomedical Advanced Research and Development Authority to support development of the vaccine.
Investors will likely ask questions related to the progress of the phase II study on mRNA-1273 and try to gain an early insight into the phase III study on the second-quarter earnings call.
Apart from mRNA-1273, Moderna is developing several other mRNA-based products targeting different indications including cancer. The company also has collaborations under which its partners use its mRNA technology for development of therapies targeting different indications. The partners pay milestone payments to Moderna, which comprise its total revenues. These revenues can vary every quarter. In the past few quarters, revenues have declined year over year due to lower collaboration revenues across its strategic alliances, particularly with AstraZeneca (AZN - Free Report) and Merck. We do not expect second-quarter results to reflect any improvement.
In March, Moderna provided an update on the impact of coronavirus pandemic on its ongoing clinical studies evaluating its pipeline candidates. The company had paused enrollment in studies evaluating its rare disease candidates and respiratory vaccine candidate. We expect it to provide an update on the future path of these clinical studies on the call.
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Moderna this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that’s not the case here. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Earnings ESP: Moderna’s Earnings ESP is -0.93%. The Zacks Consensus Estimate is pegged at a loss of 36 cents.
Zacks Rank: Moderna currently has a Zacks Rank #2.
Moderna, Inc. Price and Consensus
Moderna, Inc. price-consensus-chart | Moderna, Inc. Quote
A Stock That Warrants a Look
Here is a biotech stock that you may want to consider, as our model shows that it has the right combination of elements to post an earnings beat in its upcoming release.
Incyte Corporation (INCY - Free Report) has an Earnings ESP of +4.62% and a Zacks Rank #3.
These Stocks Are Poised to Soar Past the Pandemic
The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.
Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.
See the 5 high-tech stocks now>>